Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% ROC (Joel Greenblatt) % is 0.26% as of Jun. 2026. The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, MediPharm Labs ranks worse than 78.9% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. MediPharm Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 0.26%.
The historical rank and industry rank for MediPharm Labs's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:MLZ'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -76.97 Med: -38.95 Max: 7.59
Current: -19.48
During the past 9 years, MediPharm Labs's highest ROC (Joel Greenblatt) % was 7.59%. The lowest was -76.97%. And the median was -38.95%.
STU:MLZ's ROC (Joel Greenblatt) % is ranked worse than 78.9% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.62
vs STU:MLZ: -19.48
MediPharm Labs's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 20.10% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
MediPharm Labs ROC (Joel Greenblatt) % Related Terms
MediPharm Labs ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MLZ vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 0.26% mean?
MediPharm Labs (STU:MLZ) has a ROC (Joel Greenblatt) % of 0.26% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on MediPharm Labs and its competitors. According to the industry distribution chart, MediPharm Labs ranks #774 out of 981 companies in the Drug Manufacturers industry, placing it in the top 78.9%.
Is MediPharm Labs' ROC (Joel Greenblatt) % too high?
MediPharm Labs' current ROC (Joel Greenblatt) % is 0.26%. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.62. MediPharm Labs' value of 0.26% is 97.8% below this industry median. Based on the distribution chart, MediPharm Labs ranks #774 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MediPharm Labs' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #774 out of 981 companies for ROC (Joel Greenblatt) %. This places MediPharm Labs in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.62. MediPharm Labs' value of 0.26% is 97.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.62, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current ROC (Joel Greenblatt) % of 0.26% is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current ROC (Joel Greenblatt) % is 0.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 0.26% and 97.8% below the Drug Manufacturers industry median of 11.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current ROC (Joel Greenblatt) % is 0.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
